Orca Bio's strategy is not to sell a standalone product, but to replace the entire conventional stem cell transplant procedure. They integrate their manufacturing process directly into the existing patient and donor workflow, leveraging established infrastructure like the National Marrow Donor Program to deliver a superior alternative.

In the real world, the selection of a therapeutic modality like an antibody or peptide is often driven by a company's existing expertise and technology platform rather than a purely agnostic approach to finding the single best tool for a clinical problem. Organizations default to the tools in their toolbox.

Causeway Therapeutics strategically targets a market with no existing FDA-approved drugs. By focusing on conditions like tennis elbow, where the standard of care is limited, they are creating a new therapeutic category rather than competing in a crowded space, giving them a unique market position.

In the competitive oncology market, Step Pharma differentiates itself by highlighting its novel, "first-in-class" mechanism and excellent safety profile. This strategy attracts interest by focusing on a unique therapeutic opportunity and potential for combination therapies, rather than competing directly on incremental efficacy gains.

Facing financial challenges as Platelet Biogenesis, the company pivoted. Instead of creating complex artificial platelets, they now extract the regenerative growth factors from platelet-producing cells. This de-risked the product and focused the platform on a more achievable therapeutic, saving the company.

Instead of competing directly with an established drug, companies can target a non-overlapping, genetically defined patient population. Idea Biosciences' drug for uveal melanoma is for HLA A2-negative patients, while the approved drug KimTrac is for HLA A2-positive patients. This strategy allows for market entry without a head-to-head battle.

Palvela targets a market inefficiency by taking dermatology drugs typically sourced from compounding pharmacies for orphan diseases and developing them into proprietary, FDA-approved products. This strategy creates a regulated, reliable supply chain for rare conditions while building a valuable commercial franchise.

Paragon Therapeutics operates a venture creation factory. Instead of discovering new targets, it applies its core half-life extension technology to validated biologics to create improved "bio-better" versions. It then spins these assets out into disease-focused companies like Spire (IBD), de-risking development by focusing on engineering and execution rather than novel biology.

Rion avoids disrupting the medical platelet supply by sourcing near-expiration units from blood banks. This provides an abundant, low-cost raw material. In return, blood banks gain a revenue stream for products that would be discarded, encouraging them to maintain larger inventories for transfusions, creating a win-win.